Amarin Q3 net revenue $42.3M (-36% YoY); European revenue grows, U.S. declines on generic competition

AMARIN CORP PLCUK

2024-Q3 EPS reported -$0.08 revenue$166,308,000

Total net revenue $42.3M (-36% YoY); U.S. net product revenue $30.6M (-51%) from generic competition and CVS delisting.
European net product revenue $4.3M (up from $0.8M); VAZKEPA sales grew 19% sequentially in Spain and UK.
Net loss $25.1M ($0.06/share) vs $19.3M loss ($0.05); non-GAAP adjusted net loss $20.4M ($0.05).
Cash and investments $305.7M, flat QoQ; reaffirms cash adequate for foreseeable future.
Company committed to maintaining public listing; exploring paths to resolve issue. Virtual Analyst Day Nov 14.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.